• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Therapix Biosciences Provides Update on Planned Merger with Destiny Biosciences Global Corp.

Share:

October 15, 2019

Therapix Biosciences logo (PRNewsfoto/Therapix Biosciences)

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. (“Destiny”).

On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. If completed, the transaction will create a combined company that focuses on Therapix’s proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny’s genomics-based breeding techniques and development capabilities.

The Company previously stated that it expects to execute a definitive agreement pertaining to the merger during the third quarter of 2019. According to the Letter of Intent, the parties agreed to allow until October 31, 2019 to complete the definitive agreement before abandoning the transaction. The Company’s Board of Directors is willing to provide Destiny with additional time to complete its due diligence process. In addition, Destiny has retained an investment bank to carry out a relative valuation analysis of both companies to assist the Destiny Board of Directors in connection with the merger. Destiny informed the Company that the valuations are being completed, but initial draft results of the valuations support the transaction and the relative pricing.

Source: PR Newswire

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • AstraZeneca Bolsters Blood Cancer Pipeline with $1.27B TeneoTwo TakeoverAstraZeneca Bolsters Blood Cancer Pipeline with $1.27B TeneoTwo Takeover
  • HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug CandidateHaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
  • BD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and RegenerationBD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and Regeneration
  • Galapagos Dives Into Cell Therapy with CellPoint & AboundBio AcquisitionsGalapagos Dives Into Cell Therapy with CellPoint & AboundBio Acquisitions
  • IDE Group, Kipuwex Team up to Develop New Telehealth SolutionsIDE Group, Kipuwex Team up to Develop New Telehealth Solutions
  • 2020 Pipeline Insights on Acute Bacterial Skin and Skin Structure Infections – Collaborations, Licensing, Mergers and Acquisition, Funding & Designations2020 Pipeline Insights on Acute Bacterial Skin and Skin Structure Infections – Collaborations, Licensing, Mergers and Acquisition, Funding & Designations
  • IntegriChain Acquires the Life Sciences Division of Cumberland, Creating the Largest Data and Business Process Platform for Market Access and Commercialization of Specialty, Precision, and Retail PharmaceuticalsIntegriChain Acquires the Life Sciences Division of Cumberland, Creating the Largest Data and Business Process Platform for Market Access and Commercialization of Specialty, Precision, and Retail Pharmaceuticals
  • Edesa Biotech and Stellar Biotechnologies Complete Business CombinationEdesa Biotech and Stellar Biotechnologies Complete Business Combination

Trending This Week

  • Immuno-Oncology Pipeline Cuts Explained
  • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
  • USFDA Accepts Glenmark’s Application to Initiate a Human Trial of Molecules for Advanced Solid Tumors and Lymphomas
  • Concentra’s Buy Offer May Jeopardize Jounce’s Merger with Redx
  • Pfizer Acquires Seagen For $43B To Tackle Cancer
  • Janssen’s Novel Dengue Antiviral Demonstrates ‘strong Protection’ in Pre-Clinical Data

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications